Aarkstore - Sutent (Renal Cell Carcinoma)

1. Category : Pharmaceuticals and Healthcare Aarkstore - Sutent (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

2. Summary “Sutent (Renal Cell Carcinoma) - Analysis and Forecasts to 2022” provides Sutent sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from Our proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Our team of industry experts. Browse Complete Report – http://www.aarkstore.com/pharmaceuticals-healthcare/109483/sutent-renal-cell-carcinoma-analysis-and-forecasts-to-2022

3. Scope • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets) • Analysis and review of Sutent including sales data • Qualitative and quantitative assessment of market space • Analysis of the trends, drivers and restraints shaping and defining the markets • In-depth analysis of Sutent including efficacy, safety, pricing, competition and other details which influence its sales potential - Detailed sales forecast for 2012-2022 for Sutent in the seven major markets

4. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of competition by understanding the changing competitive landscape - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of the drug’s performance - Examine the historical sales performance of a drug in seven major markets - Obtain sales forecast for currently marketed/pipeline drug for 2012-2022 for all seven major markets

5. Table of Content 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 RCC 2.1.1 Types of Renal Cell Carcinoma 2.2 RCC Market 2.3 Epidemiology 2.4 Pathophysiology 2.5 Etiology 2.5.1 Cigarette Smoking 2.5.2 Obesity

6. List of Tables Table 1: RCC, Incidences and Mortality, 2008-2030 Table 2: RCC, TNM Classification Table 3: RCC, Fuhrman grading system Table 4: RCC, Treatment Guidelines Table 5: Sutent, Oncology, Global, Approval History Table 6 Sutent, Renal Cell Carcinoma, Drug Risk Benefit Score Table 7: Sutent, Renal Cell Carcinoma, Global, Annual Cost of Therapy, 2011 Table 8: Sutent, RCC, Global Sales Forecasts ($m), 2006–2014 Table 9: Sutent, RCC, Global Sales Forecasts ($m), 2015–2022 Table 10: Sutent, RCC, The US, Sales Forecasts ($m), 2006–2014 Table 11: Sutent, RCC, The US, Sales Forecast ($m), 2015–2022 Table 12: Sutent, RCC, The UK, Sales Forecasts ($m), 2006–2014 Table 13: Sutent, RCC, The UK, Sales Forecasts ($m), 2015–2022 Table 14: Sutent, RCC, France, Sales Forecasts ($m), 2006–2014 Table 23: Sutent, RCC, Japan, Sales Forecasts ($m), 2015–2022

7. List of Figures • Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010 • Figure 2: Total number of cigarettes consumed, The US, 1976-2006 • Figure 3: RCC, Global, Market Size Forecasts ($bn), 2010–2022 • Figure 4: RCC, Global, Incidence (in million), 2008-2030 • Figure 5: Oncology, Worldwide, Incidence (in million), 2008-2030 • Figure 6: RCC, TNM Staging System • Figure 7: RCC, Marketed drug targets • Figure 8: RCC, Surgical Management • Figure 9: Treatment Algorithm for Metastatic Renal Cell Carcinoma • Figure 10: Classification of Patients with RCC • Figure 11: Phase III results, Sutent Vs IFNa • Figure 12: Drug Model Diagram of Sutent • Figure 13: Sutent, RCC, Global Sales Forecasts ($m), 2006–2022 • Figure 14: Sutent, RCC, The US, Sales Forecasts ($m), 2006–2022

8. Related reports: • Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023 • Dupilumab (Atopic Dermatitis) - Forecast and Market Analysis to 2022 • Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 • PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022 • Dupilumab (Asthma) - Forecast and Market Analysis to 2023 • Dupilumab (Atopic Dermatitis) - Forecast and Market Analysis to 2022 • PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022 • PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023 • PharmaFocus: Vaccine Adjuvants in Infectious Disease • PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

9. Sutent (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Published: Mar 2012 | 51 Pages The report also includes information on Renal Cell Carcinoma market.. Price

10. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news